Literature DB >> 19142977

Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma.

Esther Korpershoek1, Anne J M Loonen, Suzanne Corvers, Francien H van Nederveen, Jos Jonkers, Xiaoqian Ma, Angelique Ziel-van der Made, Hanneke Korsten, Jan Trapman, Winand N M Dinjens, Ronald R de Krijger.   

Abstract

Phaeochromocytomas (PCCs) are neuro-endocrine tumours of the adrenal medulla that are usually benign, but approximately 10% of patients develop metastases. Malignant PCCs can only be diagnosed with certainty if metastases are present. Here we describe adrenal tumours generated in a Pten conditional knock-out (KO) mouse model. We characterized the molecular alterations in these tumours and compared them with human PCC. Thirty-two of 41 (78%) male Psa-Cre;Pten-loxP/loxP mice presented adrenal tumours that were shown to be PCC by histology and by immunohistochemical staining for enzymes in the catecholamine biosynthetic pathway. In 6 of 17 investigated mice, histological and immunohistochemical evidence was obtained for the presence of PCC lung metastases. Array comparative genomic hybridization (CGH) analysis of the primary tumours showed loss of chromosomes 6 and 19, which are syntenic to human 3p and 11q. Another frequent alteration found was gain of chromosome 15, which is syntenic to human chromosome 5. The molecular aberrations in the mouse model corresponded to the alterations found in a subtype of human PCC, suggesting that the PCC of the Pten KO mice might be representative of human PCC. The mouse model should allow further studies into the pathogenesis of human malignant PCCs and into therapeutic strategies for these tumours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142977     DOI: 10.1002/path.2492

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

Review 2.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

Review 3.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

4.  Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy.

Authors:  Edwin W Lai; Bharat H Joshi; Lucia Martiniova; Ritika Dogra; Toshio Fujisawa; Pamela Leland; Ronald R de Krijger; Irina A Lubensky; Abdel G Elkahloun; John C Morris; Raj K Puri; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

Review 5.  Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?

Authors:  Esther Korpershoek; Karel Pacak; Lucia Martiniova
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

6.  An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.

Authors:  Cristina Mirantes; Núria Eritja; Maria Alba Dosil; Maria Santacana; Judit Pallares; Sónia Gatius; Laura Bergadà; Oscar Maiques; Xavier Matias-Guiu; Xavier Dolcet
Journal:  Dis Model Mech       Date:  2013-02-08       Impact factor: 5.758

7.  Molecular Alterations in Dog Pheochromocytomas and Paragangliomas.

Authors:  Esther Korpershoek; Daphne A E R Dieduksman; Guy C M Grinwis; Michael J Day; Claudia E Reusch; Monika Hilbe; Federico Fracassi; Niels M G Krol; André G Uitterlinden; Annelies de Klein; Bert Eussen; Hans Stoop; Ronald R de Krijger; Sara Galac; Winand N M Dinjens
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.